PedAM
Pediatric Disease Annotations & Medicines
| Disease | essential thrombocythemia |
| Phenotype | C0040053|thrombosis |
| Sentences | 20 |
| PubMedID- 21490340 | The current study clarifies the contribution of specific disease and host characteristics to the risk of arterial versus venous thrombosis in essential thrombocythemia. |
| PubMedID- 22768743 | The paper describes two clinical cases of essential thrombocythemia (et) complicated by thrombosis in parturients. |
| PubMedID- 20623009 | This drug is often used to supplement phlebotomy for patients with polycythemia vera (pv; [2]) and to reduce significantly the incidence of recurrent thrombosis in patients with essential thrombocythemia who are at high risk [3]. |
| PubMedID- 20483636 | The development of bone marrow fibrosis and thrombosis are main causes of morbidity in essential thrombocythemia (et). |
| PubMedID- 25223529 | The current widely accepted stratification defined by age and previous thrombosis in patients with essential thrombocythemia (et) probably deserves deeper analysis. |
| PubMedID- 21062242 | Hemorrhage, thrombosis and leukemic transformation) of polycythemia vera (pv), essential thrombocythemia (et), and primary myelofibrosis (pmf), the advent of molecular biology has provided substantial molecular insight into the pathobiology of myeloproliferative neoplasia (mpn). |
| PubMedID- 22446615 | We report a 13-year-old girl who presented with isolated cerebral venous thrombosis and was diagnosed with essential thrombocythemia. |
| PubMedID- 22781379 | [very late coronary drug-eluting stent thrombosis in a patient with essential thrombocythemia: a case report of a rare association]. |
| PubMedID- 19582452 | Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous jak2 v617f mutation. |
| PubMedID- 21287350 | Established risk factors for thrombosis in essential thrombocythemia (et) include age (>/= 60 years) and previous vascular events. |
| PubMedID- 23033268 | Accurate prediction of thrombosis in essential thrombocythemia (et) provides the platform for prospective studies exploring preventive measures. |
| PubMedID- 25997869 | The impact of jak2v617f mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis. |
| PubMedID- 24889737 | Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. |
| PubMedID- 25269924 | Acute myocardial infarction and sub-acute stent thrombosis associated with occult essential thrombocythemia. |
| PubMedID- 25872987 | New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera. |
| PubMedID- 24709317 | Deep vein thrombosis occurs in 30% of patients with essential thrombocythemia, but rarely at initial diagnosis. |
| PubMedID- 22537896 | [aortic thrombosis in a patient with essential thrombocythemia]. |
| PubMedID- 21142409 | This case describes the medical history of a 61-year-old woman treated for cerebral venous thrombosis (cvt) leading to diagnosis of essential thrombocythemia (et). |
| PubMedID- 24617727 | Decanucleotide insertion polymorphism of f7 significantly influences the risk of thrombosis in patients with essential thrombocythemia. |
| PubMedID- 25170413 | The risk of thrombosis is high in patients with essential thrombocythemia. |
Page: 1